Articles From: AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol to Astro-Med, Inc. Promotes Gregory Woods to President & Chief Operating Officer


2013/11/12
AstraZeneca (NYSE:AZN) today announced their support of the release of the “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,” which recommends use of statin therapy for patients across four major groups at risk for a heart attack, stroke or major cardiovascular event.
Sign-up for AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol investment picks
2014/2/3
AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
Sign-up for AstraZeneca Completes Acquisition of Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb investment picks
By Ian Walker LONDON--Biopharmaceutical company AstraZeneca PLC (AZN.LN) said Friday the European Commission has approved Fluenz Tetra for the prevention of seasonal influenza in children.
Sign-up for AstraZeneca Gets EU Approval for Influenza Drug Fluenz Tetra investment picks
2013/9/30
LONDON--Drug group AstraZeneca PLC (AZN.LN) said Monday that the European Medicines Agency has accepted its marketing authorization application for Olabarib, a treatment for ovarian cancer.
Sign-up for AstraZeneca Gets European Marketing Approval for Ovarian Cancer Drug investment picks
2014/3/3
By Tapan Panchal LONDON--AstraZeneca PLC (AZN.LN) said Monday the U.S. Food and Drug Administration approved its Bydureon Pen for the once-weekly treatment of adults with type 2 diabetes.
Sign-up for AstraZeneca Gets FDA Approval for Bydureon Pen investment picks
New Trial Triggers Milestone Payment to Array BOULDER, Colo.
Sign-up for AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer investment picks
2014/3/19
AstraZeneca (NYSE: AZN) today launched NEXIUM Direct, a program that provides eligible patients the option of having brand-name NEXIUM delivered directly to their home.
Sign-up for AstraZeneca Launches NEXIUM® (Esomeprazole Magnesium) Direct-to-Patient Program investment picks
2014/2/20
AstraZeneca (NYSE:AZN) announced today that, in 2013, it provided nearly $975 million in savings to more than 567,000 patients in the United States through its patient assistance programs.
Sign-up for AstraZeneca Patient Assistance Programs Provided More Than Half a Million Patients with Free Medicine in 2013 investment picks
FRANKFURT--The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) third-quarter results, based on a poll of eight analysts conducted by Dow Jones Newswires (figures in million dollars, EPS and dividend in dollar, target price in pence, according to IFRS). Earnings figures are scheduled to be released October 31.
Sign-up for AstraZeneca plc 3Q 2013 -- Forecast investment picks
2014/2/3
FRANKFURT--The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) fourth-quarter results, based on a poll of nine analysts conducted by Dow Jones Newswires (figures in million dollars, EPS and dividend in dollar, target price in pence, according to IFRS). Earnings figures are scheduled to be released February 6.
Sign-up for AstraZeneca plc 4Q 2013 -- Forecast investment picks
TIDMAZN RNS Number : 0717Z AstraZeneca PLC 03 February 2014 ASTRAZENECA COMPLETES THE ACQUISITION OF BRISTOL-MYERS SQUIBB SHARE OF GLOBAL DIABETES ALLIANCE AstraZeneca today announced that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb's interests in the companies' diabetes alliance.
Sign-up for AstraZeneca PLC AZ completes BMS diabetes acquisition investment picks
2013/10/7
TIDMAZN RNS Number : 8422P AstraZeneca PLC 07 October 2013 MEDIMMUNE COMPLETES ACQUISITION OF AMPLIMMUNE AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm, completed its acquisition of Amplimmune, a privately-held, US-based biologics company focused on developing novel therapeutics in cancer immunology.
Sign-up for AstraZeneca PLC MedImmune completes Amplimmune acquisition investment picks
By Ed Ballard AstraZeneca PLC (AZN.LN) Wednesday announced the sale of its Alderley Park site on a former country estate in Cheshire, U.K., as part of a plan announced last March to set up a new research and development base in Cambridge in 2016.
Sign-up for Astrazeneca Sells Alderley Park Site, to Move R&D Base to Cambridge investment picks
2013/10/22
By Rory Gallivan LONDON--Drug maker AstraZeneca PLC (AZN.LN) said Tuesday that it has started a phase III program for its lung cancer treatment selumetinib following promising phase II results.
Sign-up for AstraZeneca Starts Phase III Program for Lung Cancer Treatment investment picks
By Ian Walker LONDON--Global biopharmaceutical firm AstraZeneca PLC (AZN.LN) Thursday confirmed it is buying Bristol-Myers Squibb Co.'s (BMY) entire stake in the two companies' diabetes venture for up to $4.1 billion.
Sign-up for AstraZeneca to Buy Bristol-Myers' Share of Diabetes Pact for Up to $4.1 Billion investment picks
2014/1/22
By Jana Weigand LONDON--British-Swedish pharmaceutical firm AstraZeneca PLC (AZN.LN) and U.S. firm Bristol-Myers Squibb Co.
Sign-up for AstraZeneca, Bristol-Myers Squibb Secure EU Approval for Xigduo investment picks
LONDON--Pharmaceutical firms AstraZeneca PLC (AZN.LN) and Shionogi & Co.
Sign-up for AstraZeneca, Shionogi Settle Crestor Arbitration investment picks
By Razak Musah Baba LONDON--Research-based biopharmaceutical company AstraZeneca PLC said Tuesday the U.S. Food and Drug Administration approved orphan drug MYALEPT.
Sign-up for AstraZeneca: FDA Approves Myalept For Leptin Deficiency Treatment investment picks
2013/12/17
LONDON--AstraZeneca PLC (AZN.LN) Tuesday responded to reports that another drug company launched an esomeprazole strontium product in the U.S., saying the development won't have an impact on its financial guidance for 2013.
Sign-up for AstraZeneca: No FY13 Impact From Hanmi Esomeprazole Strontium Launch investment picks
By Rory Gallivan LONDON--AstraZeneca PLC (AZN.LN) said Friday that a Phase III study of its gout treatment lesinurad demonstrated its effectiveness in patients who can't take other drugs, but also resulted in adverse effects including diarrhea, nausea and constipation.
Sign-up for AstraZeneca's Gout Treatment Demonstrates Effectiveness in Study investment picks
By Rory Gallivan LONDON--AstraZeneca PLC (AZN.LN) said Tuesday that the United States Food and Drug Administration has accepted its New Drug Application for naloxegol, a treatment for constipation caused by opioid medicines used to treat pain.
Sign-up for AstraZeneca's New Drug Application for Naloxegol Accepted investment picks
2013/12/9
TUCSON, Ariz.
Sign-up for Astrium, Raytheon team to compete for NATO ballistic missile defense work investment picks
2013/9/4
http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1048017&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med Announces Contract With Russia's United Aircraft Corporation-Integration Center (a subsidiary of the United Aircraft Corporation) for ToughWriter(R) 5 Flight Deck Printers investment picks
http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1038451&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med Announces Transavia Contract for ToughWriter(R) 5 Flight Deck Printers investment picks
http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1072642&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med CEO Everett Pizzuti to Retire; Board Appoints Gregory Woods as Successor investment picks
http://media.marketwire.com/attachments/201309/TN-188373_Kiaro!_200_label_printer.jpg New Kiaro! 200 wide label printer by QuickLabel Systems, Astro-Med, Inc. http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1052985&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med Introduces QuickLabel Systems' Kiaro! 200 Color Label Printer for Wide Labels investment picks
2014/3/10
http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1096360&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med, Inc. Announces Meeting Date Change for 2014 Annual Meeting of Shareholders investment picks
2014/2/12
http://media.marketwire.com/attachments/201304/59888_astromedlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1089245&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med, Inc. Completes Acquisition of Miltope Aerospace Printer Business investment picks
2014/3/4
http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1094699&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med, Inc. Directors Declare Quarterly Dividend; Fourth Quarter and FY2014 Sales and Earnings Report Scheduled for March 18 investment picks
http://media.marketwire.com/attachments/200603/251083_astromedscannedlogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1046677&ProfileId=051205&sourceType=1 WEST WARWICK, RI --
Sign-up for Astro-Med, Inc. Promotes Gregory Woods to President & Chief Operating Officer investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: AstraZeneca Applauds the Release of New U.S. Guideline for Management of Blood Cholesterol to Astro-Med, Inc. Promotes Gregory Woods to President & Chief Operating Officer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity